Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma

Inclusion criteria

• ✓. The patients must have histologically confirmed primary gastric MALT lymphoma by REAL/WHO classification
• ✓. The patient must have no prior chemotherapy or radiotherapy for his/her gastric MALT lymphoma
• ✓. Patients must have evaluable disease by endoscopy and/or the nodal status by computed tomography 3.1 If patients have endoscopic lesions without computed tomography-demonstrating lesions are eligible.
• ✓.2 Endoscopic ultrasonography (EUS) is optional to evaluate the depth of tumor infiltration and for status of perigastric lymph node enlargement
• ✓. Patients must have documented to have no HP infection before treatment, which will be evaluated by the following tests: histology, rapid urease test (CLO-test), C-13 urease breath test, HP stool antigen, and serology; and all of the five tests have to be negative for the diagnosis of no evidence of HP infection.
• ✓. Patients must have either stage IE or IIE1 disease, according to an adaptation of the Ann Arbor staging system modified by Musshoff for primary extranodal lymphoma.
• ✓. Patients must have signed the informed consent and agree to provide achieved pathologic material and tumor biopsy for translational study
• ✓. Patients must have signed the informed consent and agree to provide achieved blood samples for potential serum molecular studies and fecal samples for researches of gut microbiota